

EMA/93290/2021

European Medicines Agency decision

P/0116/2021

of 17 March 2021

on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / abacavir / lamivudine (Triumeq), (EMA-001219-PIP01-11-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0116/2021

of 17 March 2021

on the acceptance of a modification of an agreed paediatric investigation plan for dolutegravir / abacavir / lamivudine (Triumeq), (EMA-001219-PIP01-11-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0287/2012 issued on 23 November 2012, decision P/0069/2015 issued on 1 April 2015, decision P/0308/2015 issued on 21 December 2015, decision P/0229/2017 issued on 9 August 2017 and the decision P/0018/2019 issued on 3 January 2019,

Having regard to the application submitted by ViiV Healthcare UK Limited on 23 October 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver.

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for dolutegravir / abacavir / lamivudine (Triumeq), film-coated tablet, dispersible tablet, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to ViiV Healthcare UK Limited, 980 Great West Road, TW8 9GS - Brentford, United Kingdom.

EMA/PDCO/610287/2020
Amsterdam, 29 January 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001219-PIP01-11-M05

Scope of the application

Active substance(s):

Dolutegravir / abacavir / lamivudine

Invented name:

Triumeq

Condition(s):

Treatment of human immunodeficiency virus (HIV-1) infection

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Dispersible tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

ViiV Healthcare UK Limited

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, ViiV Healthcare UK Limited submitted to the European Medicines Agency on 23 October 2020 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines

Agency's decision P/0287/2012 issued on 23 November 2012, decision P/0069/2015 issued on 1 April 2015 and decision P/0308/2015 issued on 21 December 2015 and the decision P/0229/2017 issued on 9 August 2017 and the decision P/0018/2019 issued on 3 January 2019.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 1 December 2020.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of human immunodeficiency virus (HIV-1) infection

The waiver applies to:

- the paediatric population from birth to less than 24 months;
- film-coated tablets, dispersible tablets, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition

Treatment of human immunodeficiency virus (HIV-1) infection

2.1.1. Indication(s) targeted by the PIP

Treatment of human immunodeficiency virus (HIV-1) infection

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

Dispersible tablet

2.1.4. Measures

Area	Number of studies	Description
Quality-related studies	1	Study 1 Development of a dispersible tablet.
Non-clinical studies	0	Not applicable
Clinical studies	2	Study 2 Multicentre, open-label, non-comparative study to evaluate pharmacokinetics, safety, tolerability and antiviral activity of dolutegravir in HIV-1 infected infants, children and adolescents from 4 weeks to less than 18 years of age

		<i>This study is the same as study 1 of the dolutegravir PIP EMEA-000409-PIP01-08-M03 and subsequent modifications thereof.</i> Study 3 Open-label, multicentre, multiple dose, trial to evaluate pharmacokinetics and safety of DTG/3TC/ABC in children from 2 to less than 12 years of age with Human Immunodeficiency Virus Infection
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By September 2022.
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of human immunodeficiency virus (HIV-1) infection

Authorised indication(s):

- Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg (see sections 4.4 and 5.1).

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin (see section 4.4). Abacavir should not be used in patients known to carry the HLA-B*5701 allele.

Authorised pharmaceutical form(s):

Film-coated tablet

Authorised route(s) of administration:

Oral use